Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1/2 2Phase 3 1Phase 1 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Sarcoma 1Genitourinary 1CNS 1

Conditions

Rectal Neoplasms 1Pancreatic Neoplasms 1Colonic Neoplasms 1Advanced Gastrointestinal Stromal Tumor (GIST) 1

Interventions

Gemcitabine 153Oxaliplatin 124Fluorouracil 108Capecitabine 105pembrolizumab 92Bevacizumab 79Leucovorin 76Irinotecan 72Nivolumab 70130-nm albumin-bound paclitaxel 68Paclitaxel 62Cisplatin 62Cetuximab 60Cyclophosphamide 47Albumin-Bound Paclitaxel 45Radiotherapy 39Docetaxel 36durvalumab 33Sorafenib 32Taxes 29Carboplatin 27fludarabine 26tislelizumab 25Drug Therapy 25atezolizumab 23Folfox protocol 23regorafenib 20lenvatinib 19Ipilimumab 19sintilimab 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × infigratinib × Gastrointestinal × Clear all
NCT02257541 2020-03-30

BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)

Memorial Sloan Kettering Cancer Center

Phase 1/2 Completed
16 enrolled 14 charts
GastrointestinalSarcoma

Advanced Gastrointestinal Stromal Tumor (GIST)

NCT02575508 2016-05-20

Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer

Roswell Park Cancer Institute

Phase 1/2 Withdrawn
Gastrointestinal

Colonic Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡